title: Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) influenza virus.
abstract: The pandemic 2009 H1N1 influenza virus broke out in North America and spread rapidly throughout the world. The type I interferon (IFN) response represents one of the first lines of defense against influenza virus infections. In this study, the protective potential of human exogenous IFN-ω against pandemic 2009 A (H1N1) influenza virus was assessed both in vitro and in guinea pigs. The viral loads of pandemic 2009 A (H1N1) influenza virus strains A/California/04/2009 and A/Beijing/501/2009 were reduced by up to 5000-fold in Caco-2 cells by the addition of human IFN-ω. With daily intranasal treatment with human IFN-ω the viral load of pandemic 2009 A (H1N1) influenza virus strain A/California/04/2009 decreased by 1000-fold in lung tissues of guinea pigs. These results provide strong support for the application of human IFN-ω pretreatment to human influenza control.
authors: State Key Laboratory of Pathogens and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
authors: Chun'e
authors: C
authors: Xu
authors: Xiaohong
authors: X
authors: Song
authors: Ling
authors: L
authors: Fu
authors: Dayong
authors: D
authors: Dong
authors: Shipo
authors: S
authors: Wu
authors: Guanlin
authors: G
authors: Li
authors: Shaoqiong
authors: S
authors: Yi
authors: Ting
authors: T
authors: Yu
authors: Rui
authors: R
authors: Yu
authors: Lihua
authors: L
authors: Hou
authors: Wei
authors: W
authors: Chen
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D018938:Caco-2 Cells; D002460:Cell Line; D004195:Disease Models, Animal; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects* / Q000276:immunology / Q000472:pathogenicity; D007370:Interferon Type I / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D008168:Lung / Q000821:virology; D009976:Orthomyxoviridae Infections / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D058873:Pandemics; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D007370:Interferon Type I; D011994:Recombinant Proteins; C063743:interferon omega 1